{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:45:00Z","timestamp":1791308700198,"version":"4.3.1"},"reference-count":106,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T00:00:00Z","timestamp":1441584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>Progressive multifocal leukoencephalopathy (PML) is a rare but debilitating and frequently fatal viral disease of the central nervous system, primarily affecting individuals with chronically and severely suppressed immune systems. The disease was relatively obscure until the outbreak of HIV\/AIDS, when it presented as one of the more frequent opportunistic infections in this immune deficiency syndrome. It attracted additional attention from the medical and scientific community following the discovery of significant PML risk associated with natalizumab, a monoclonal antibody used for treatment of relapsing\u2013remitting multiple sclerosis. This was followed by association of PML with other immunosuppressive or immunomodulating drugs. PML is currently untreatable disease with poor outcomes, so it is a significant concern when developing new immunotherapies. Current prophylaxis and treatment of PML are focused on immune reconstitution, restoration of immune responses to JC virus infection, and eventual suppression of immune reconstitution inflammatory syndrome. This approach was successful in reducing the incidence of PML and improved survival of PML patients with HIV infection. However, the outcome for the majority of PML patients, regardless of their medical history, is still relatively poor. There is a high unmet need for both prophylaxis and treatment of PML. The aim of this review is to discuss potential drug candidates for prophylaxis and treatment of PML with a critical review of previously conducted and completed PML treatment studies as well as to provide perspectives for future therapies.<\/jats:p>","DOI":"10.1177\/1756285615602832","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T21:39:10Z","timestamp":1441661950000},"page":"255-273","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":203,"title":["Progressive multifocal leukoencephalopathy: current treatment options and future perspectives"],"prefix":"10.1177","volume":"8","author":[{"given":"Dejan","family":"Pavlovic","sequence":"first","affiliation":[{"name":"MedImmune, Gaithersburg MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriani C.","family":"Patera","sequence":"additional","affiliation":[{"name":"MedImmune, Gaithersburg MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Nyberg","sequence":"additional","affiliation":[{"name":"AstraZeneca, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Gerber","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Liu","sequence":"additional","affiliation":[{"name":"The Progressive Multifocal Leukeoncephalopathy Consortium Secretariat, Drinker Biddle & Reath LLP, 1500 K Street NW, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Progressive Multifocal Leukeoncephalopathy Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,9,7]]},"reference":[{"key":"bibr1-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.825"},{"key":"bibr2-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182768983"},{"issue":"1","key":"bibr3-1756285615602832","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/brain\/81.1.93","volume":"81","author":"Astrom K.","year":"1958","journal-title":"Brain"},{"key":"bibr4-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1080\/13550280152537157"},{"key":"bibr5-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-78-3-659"},{"key":"bibr6-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.221"},{"key":"bibr7-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis668"},{"key":"bibr8-1756285615602832","doi-asserted-by":"publisher","DOI":"10.3109\/13550289809113482"},{"key":"bibr9-1756285615602832","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1212\/WNL.42.1.257","volume":"42","author":"Berger J.","year":"1992","journal-title":"Neurology"},{"key":"bibr10-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02269.x"},{"key":"bibr11-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01737-09"},{"key":"bibr12-1756285615602832","unstructured":"Biogen-Idec (2011) Natalizumab PML risk update, July 2011. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Presentation\/2011\/07\/WC500109645.pdf (accessed August 2015)"},{"key":"bibr13-1756285615602832","unstructured":"Biogen-Idec (2014) Natalizumab PML risk update, February 2014. Available at: http:\/\/multiple-sclerosis-research.blogspot.com\/2014\/03\/natalizumab-pml-risk-update-february.html (accessed August 2015)."},{"key":"bibr14-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"bibr15-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.21.10290-10299.2001"},{"key":"bibr16-1756285615602832","unstructured":"Boland C. (2012) JC virus vaccine. Patent EP 2465532 A1."},{"key":"bibr17-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.164"},{"key":"bibr18-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-08"},{"key":"bibr19-1756285615602832","unstructured":"Brosgart C., Roberts T., Safrin S. (1997) Cidofovir therapy for PML in two AIDS patients. [Abstract I-5] 37th ICAAC."},{"key":"bibr20-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-002-0481-4"},{"key":"bibr21-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28712"},{"key":"bibr22-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2008.557"},{"key":"bibr23-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1080\/13550280802235916"},{"key":"bibr24-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70226-9"},{"key":"bibr25-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1080\/13550280152537247"},{"key":"bibr26-1756285615602832","author":"Clifford D.","year":"2014","journal-title":"J Neurovirol"},{"key":"bibr27-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.103"},{"key":"bibr28-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-013-0173-y"},{"key":"bibr29-1756285615602832","unstructured":"ClinicSpeak (2015) Natalizumab PML update - Q4 2014, January 2015. Available at: http:\/\/multiple-sclerosis-research.blogspot.com\/2015\/01\/clinicspeak-natalizumab-pml-update-q4.html (accessed August 2015)."},{"key":"bibr30-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-304897"},{"key":"bibr31-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10827"},{"key":"bibr32-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830a5043"},{"key":"bibr33-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1177\/08830738050200031301"},{"key":"bibr34-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129694."},{"key":"bibr35-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1126\/science.1103492"},{"key":"bibr36-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1086\/595299"},{"key":"bibr37-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2008.07.032"},{"key":"bibr38-1756285615602832","first-page":"954","volume":"8","author":"Epperla N.","year":"2013","journal-title":"J Hospital Med"},{"key":"bibr39-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1097\/01.NT.0000397959.27386.55"},{"key":"bibr40-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2004.06.010"},{"key":"bibr41-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu074"},{"key":"bibr42-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020967"},{"key":"bibr43-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1304828"},{"key":"bibr44-1756285615602832","unstructured":"Grimm J., Martin R., Combaluzier B. (2014) Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases. Patent WO2014102399A1."},{"key":"bibr45-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00046-11"},{"key":"bibr46-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805073381903"},{"key":"bibr47-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.23.11406"},{"key":"bibr48-1756285615602832","doi-asserted-by":"publisher","DOI":"10.3109\/13550289809114545"},{"key":"bibr49-1756285615602832","doi-asserted-by":"publisher","DOI":"10.3109\/13550289809114533"},{"key":"bibr50-1756285615602832","unstructured":"Jelcic I., Martin R., Schippling S., Sospreda M., Yousef S. (2013) Polyoma virus JC peptides and proteins in vaccination and diagnostic applications. Patent WO 2013014134 A2."},{"key":"bibr51-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00837-10"},{"key":"bibr52-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-32957-9_18"},{"issue":"19","key":"bibr53-1756285615602832","first-page":"E4","volume":"10","author":"Kappos L.","year":"2011","journal-title":"Neurol Rev"},{"key":"bibr54-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705682"},{"key":"bibr55-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2009.03.001"},{"key":"bibr56-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1993.1517"},{"key":"bibr57-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1086\/598335"},{"key":"bibr58-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705598"},{"key":"bibr59-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.32.10.2359-2363.1994"},{"key":"bibr60-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.35.5.1255-1257.1997"},{"key":"bibr61-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-32957-9_2"},{"key":"bibr62-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20933"},{"key":"bibr63-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.33.6.1448-1451.1995"},{"key":"bibr64-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000183064.10227.b5"},{"key":"bibr65-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-158"},{"key":"bibr66-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-014-0272-4"},{"key":"bibr67-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200209060-00012"},{"key":"bibr68-1756285615602832","unstructured":"Martin R., Sospedra M., Jelcic I., Yousef S., Schippling S. (2011) Polyoma virus JC peptides and proteins in vaccination and diagnostic applications. Patent EP2548567 A1."},{"key":"bibr69-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1789.2007.00878.x"},{"key":"bibr70-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21710"},{"key":"bibr71-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1038\/nri2970"},{"key":"bibr72-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-012-0107-0"},{"key":"bibr73-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1002\/art.24966"},{"key":"bibr74-1756285615602832","doi-asserted-by":"crossref","unstructured":"Mommeja-Marin H., Marty F., Boeckh M., Winston D., Rowley S., Godkin S. (2012) CMX001, a novel broad spectrum antiviral, may mitigate signs of BK virus (BKV) associated bladder and kidney end-organ damage. Poster at ICTS, July 2012","DOI":"10.1097\/00007890-201211271-01112"},{"key":"bibr75-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.5.1066"},{"key":"bibr76-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31818b62c8"},{"key":"bibr77-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00729-13"},{"key":"bibr78-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2012.03.014"},{"key":"bibr79-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199707)52:3<243::AID-JMV2>3.0.CO;2-2"},{"key":"bibr80-1756285615602832","unstructured":"Newman M. (2014) Orphan Drug Designation Granted to Treatment for Rare Multiple Sclerosis Drug Complication. Multiple Sclerosis News Today. Available at: http:\/\/multiplesclerosisnewstoday.com\/2014\/05\/22\/orphan-drug-designation-granted-treatment-rare-multiple-sclerosis-drug-complication\/ (accessed August 2015)"},{"key":"bibr81-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23443"},{"key":"bibr82-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1080\/13550280390241223"},{"key":"bibr83-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.13.7270-7273.2004"},{"key":"bibr84-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)91777-6"},{"key":"bibr85-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1159\/000333780"},{"key":"bibr86-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq359"},{"key":"bibr87-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300511"},{"key":"bibr88-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.5.2288-2292.2000"},{"key":"bibr89-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701010"},{"key":"bibr90-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01086-06"},{"key":"bibr91-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701568"},{"key":"bibr92-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201248"},{"key":"bibr93-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1089\/088922201750251981"},{"key":"bibr94-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1080\/713831540"},{"key":"bibr95-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.2.257"},{"key":"bibr96-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511421919"},{"key":"bibr97-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu682"},{"key":"bibr98-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00609-10"},{"key":"bibr99-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70040-5"},{"key":"bibr100-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822e55e7"},{"key":"bibr101-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000343510.08643.74"},{"key":"bibr102-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1086\/314496"},{"key":"bibr103-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(92)90040-V"},{"key":"bibr104-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1086\/520514"},{"key":"bibr105-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182749f17"},{"key":"bibr106-1756285615602832","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200503173521125"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756285615602832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756285615602832","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756285615602832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T23:35:51Z","timestamp":1740785751000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756285615602832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,7]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1177\/1756285615602832"],"URL":"https:\/\/doi.org\/10.1177\/1756285615602832","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,7]]}}}